The FDA Has Granted Orphan Drug Designation To MAIA Biotechnology's Lead Asset THIO, A Cancer Telomere-targeting Agent, For The Treatment Of Glioblastoma
The FDA Has Granted Orphan Drug Designation To MAIA Biotechnology's Lead Asset THIO, A Cancer Telomere-targeting Agent, For The Treatment Of Glioblastoma
美国食品药品管理局已向MAIA Biotechnology的主要资产THIO（一种癌症端粒靶向剂）授予孤儿药称号，用于治疗胶质母细胞瘤
The FDA Has Granted Orphan Drug Designation To MAIA Biotechnology's Lead Asset THIO, A Cancer Telomere-targeting Agent, For The Treatment Of Glioblastoma
美国食品药品管理局已向MAIA Biotechnology的主要资产THIO（一种癌症端粒靶向剂）授予孤儿药称号，用于治疗胶质母细胞瘤